Peptide and protein-based cancer vaccines usually fail to elicit efficient immune responses
against tumors. However, delivery of these peptides and proteins as components within …

The concept of using plants to produce high‐value pharmaceuticals such as vaccines is 20
years old this year and is only now on the brink of realisation as an established technology …

The use of plants for the production of virus‐like nanoparticles (VNPs) dates back to
separating natural empty capsids of plant viruses from whole virions nearly 70 years ago …

Virus-like particles (VLPs) consist of viral structural proteins that, when overexpressed,
spontaneously self-assemble into particles that are antigenically indistinguishable from …

Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19
pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate …

Understanding the pharmacokinetics, blood compatibility, biodistribution and clearance
properties of nanoparticles is of great importance to their translation to clinical application. In …

Global demand for recombinant proteins has steadily accelerated for the last 20 years.
These recombinant proteins have a wide range of important applications, including vaccines …

Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that
mimic the native architecture of viruses but lack the viral genome. VLPs have emerged as a …

In the molecular farming area, transient expression approaches for pharmaceutical proteins
production, mainly recombinant monoclonal antibodies and vaccines, were developed …

Immunostimulatory agents, including adjuvants, cytokines, and monoclonal antibodies, hold
great potential for the treatment of cancer. However, their direct administration often results …